Risperidone augmentation of clozapine

Pharmacopsychiatry
R H McCarthy, K G Terkelsen

Abstract

While effective as a single agent in a significant proportion of treatment refractory patients, clozapine is often used in combination with other medications, including classical neuroleptics (1), mood stabilizers and antidepressants (2), benzodiazepines (3) and lithium (4). In Denmark, where clozapine has been in near continuous use since 1975, up to 60% of clozapine patients receive additional medication (4). Classical neuroleptics, often at antipsychotic levels, are the medications most frequently added, and are used in 30-35% of patients receiving clozapine (4,5). Clozapine, due to its low D2-blocking effect, may be therapeutically insufficient to contain symptoms and additional agents may be required (4). In controlled clinical trials risperidone has been shown to be superior to haloperidol (6), but has not yet been rigorously compared to clozapine. In light of its established efficacy and pharmacological profile (7) risperidone may be reasonably construed to be a medication with efficacy somewhere between clozapine and classical neuroleptics. As such, it may be especially well suited for use with clozapine as a part of an augmentation strategy. There are no reports in the literature describing the concurrent use of risper...Continue Reading

Citations

Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vladimir LernerRael D Strous
Jun 13, 2003·The Journal of Head Trauma Rehabilitation·Elie Paul ElovicJoseph H Ricker
Mar 23, 2005·Der Nervenarzt·M Zink, H Dressing
Apr 1, 1997·Journal of Clinical Psychopharmacology·S A ChongH S Lee
Feb 16, 2005·Clinical Neuropharmacology·Vassilis P KontaxakisGeorge N Christodoulou
Apr 7, 2007·Clinical Neuropharmacology·Iván Lerma-CarrilloCecilio Alamo
Jul 26, 2005·Journal of Psychiatric Practice·Vijayalakshmy PatrickSteven Schleifer
Dec 6, 2008·Journal of Psychiatric Practice·Anand K Pandurangi, Alican Dalkilic
Sep 28, 2005·CNS Drugs·Gary RemingtonChekkera Shammi
Jan 1, 2002·Expert Review of Neurotherapeutics·Leslie Citrome, Jan Volavka
Aug 24, 2005·Human Psychopharmacology·Franca CentorrinoRoss J Baldessarini
Dec 18, 2001·Biological Psychiatry·R R Conley, D L Kelly
May 1, 2003·Expert Review of Neurotherapeutics·Jambur AnanthSarath Gunatilake
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Jul 6, 2000·The Australian and New Zealand Journal of Psychiatry·A Adesanya, C Pantelis
Aug 11, 2006·European Archives of Psychiatry and Clinical Neuroscience·Vassilis P KontaxakisGeorge N Christodoulou
May 1, 1999·Acta Psychiatrica Scandinavica·A L MoreraJ L Cano-Muñoz
Dec 4, 2008·Clinical Neuropharmacology·Ivan Lerma-CarrilloEnrique Baca-García
Dec 22, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Constantin TranulisEmmanuel Stip
Mar 7, 2006·Clinical Neuropharmacology·Fayçal MouaffakDavid Gourion
May 19, 2004·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Doron MazehAbraham Weizman
Jun 1, 1996·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S A ChongH S Lee
Oct 22, 2005·Clinical Neuropharmacology·Marc ZiegenbeinHeike E Kuenzel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here